Schrödinger (NASDAQ: SDGR)
Schrödinger Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Schrödinger Company Info
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.
News & Analysis
Is Schrödinger Stock a Buy Now?
Its groundbreaking work is winning it some powerful fans, but it's still risky.
This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?
There's more to the AI boom than Microsoft and ChatGPT.
Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months
Cathie Wood and Bill Gates like this stock, too.
This AI Biotech Stock Is Already Profitable. Should You Buy It?
Its future could be bright, but don't get too attached to its successes right now.
3 AI Drug Discovery Stocks to Watch
The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.
Here's Bill Gates' Top Artificial Intelligence Stock Other Than Microsoft -- and Wall Street Thinks It Can Soar Nearly 70% Over the Next 12 Months
Bill Gates is excited about AI. And he seems to really like the opportunities for this AI company.
Why Shares of Schrödinger Are Falling Thursday
The company released second-quarter earnings after the markets closed on Wednesday.
This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?
Its software platform could become a core tool for many businesses in biopharma.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.